📌 What is the IL28B RS12979860 Genotyping Test?
A genetic test that analyzes variations in the IL28B gene (rs12979860 SNP) using Polymerase Chain Reaction (PCR).
The IL28B gene encodes Interferon Lambda-3, which plays a role in immune response against viral infections.
This test is mainly used to predict treatment response to hepatitis C virus (HCV) therapy.
🎯 Purpose of the Test
✅ Helps determine a patient’s likelihood of responding to interferon-based treatment for Hepatitis C.
✅ Identifies genetic variations (CC, CT, or TT genotypes) linked to HCV treatment success or failure.
✅ Assists in treatment planning and prognosis for chronic HCV patients.
📊 Normal Ranges & Interpretation
🔹 CC Genotype (Favorable Response) – Higher chance of successful response to interferon-based HCV therapy.
🔹 CT or TT Genotype (Less Favorable Response) – Lower chance of responding to interferon-based treatment.
(There is no “normal” or “abnormal” result; interpretation is based on genotype.)
📝 Test Procedure
1️⃣ A blood sample or buccal swab is collected.
2️⃣ DNA is extracted, and the rs12979860 SNP in the IL28B gene is analyzed using PCR technology.
3️⃣ Results determine the patient’s genetic variant (CC, CT, or TT genotype).
⚠️ Who Should Get Tested?
🔹 Patients diagnosed with chronic Hepatitis C (HCV), especially HCV genotype 1.
🔹 Individuals being considered for interferon-based antiviral therapy.
🔹 Patients with a history of poor response to HCV treatment.
✅ Why is This Test Important?
✔️ Helps predict treatment success for Hepatitis C therapy.
✔️ Guides personalized treatment decisions to avoid ineffective therapies.
✔️ Identifies patients who may require alternative or more aggressive treatment approaches.